Sfoglia per Autore VALABREGA, Giorgio
ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells.
2003-01-01 VALABREGA G; FAGIOLI F; CORSO S; MADON E; BRACH DEL PREVER A; BIASIN E; LINARI A; M. AGLIETTA; GIORDANO S.
Trastuzumab-based combination therapy for breast cancer
2004-01-01 MONTEMURRO F; VALABREGA G; AGLIETTA M
The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005
2005-01-01 MONTEMURRO F; VALABREGA G; GARETTO L; ALIBERTI S; GRIGNANI G; ORTEGA C; LEONE F; PONZONE R; AGLIETTA M
TGFalpha expression impairs Trastuzumab-induced HER2 downregulation
2005-01-01 VALABREGA G; MONTEMURRO F; SAROTTO I; PETRELLI A; RUBINI P; TACCHETTI C; AGLIETTA M; COMOGLIO PM; GIORDANO S
Controversies in breast cancer: adjuvant and neoadjuvant therapy
2005-01-01 F. MONTEMURRO; S. REDANA; G. VALABREGA; M. AGLIETTA
Trastuzumab treatment in breast cancer
2006-01-01 MONTEMURRO F; VALABREGA G; AGLIETTA M
Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer
2006-01-01 MONTEMURRO F; GATTI M; REDANA S; JACOMUZZI ME; NANNI D; DURANDO A; POPOLO M; PONZONE R; ROSSI A; ALBIERI V; VALABREGA G; SISMONDI P; GABRIELE P; AGLIETTA M
Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy
2006-01-01 F. MONTEMURRO; M. DONADIO; M. CLAVAREZZA; S. REDANA; M.E. JACOMUZZI; G. VALABREGA; S. DANESE; G. VIETTI-RAMUS; A. DURANDO; M. VENTURINI; M. AGLIETTA
Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007
2007-01-01 MONTEMURRO F; REDANA S; VALABREGA G; AGLIETTA M
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
2007-01-01 VALABREGA G; MONTEMURRO F; AGLIETTA M
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity
2007-01-01 MONTEMURRO F; VALABREGA G; AGLIETTA M
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era
2008-01-01 Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; Paolo dei Tos A; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study
2008-01-01 MONTEMURRO F; REDANA S; NOLE' F; DONADIO M; JACOMUZZI ME; VALABREGA G; VIALE G; SAPINO A; AGLIETTA M
Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial
2008-01-01 MONTEMURRO F; REDANA S; VALABREGA G; MARTINELLO R; AGLIETTA M; PALMIERO R
Multitarget drugs: the present and the future of cancer therapy
2009-01-01 Petrelli A; Valabrega G.
Trastuzumab Beyond Disease Progression: Case Closed?
2009-01-01 Valabrega G; Aglietta M; Montemurro F
Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer.
2010-01-01 Montemurro F; Rossi V; Nolè F; Redana S; Donadio M; Martinello R; Verri E; Valabrega G; Rocca MC; Jacomuzzi ME; Viale G; Sapino A; Aglietta M.
Role of trastuzumab in the management of HER2-positive metastatic breast cancer.
2010-01-01 Milani A;Montemurro F;Gioeni L;Aglietta M;Valabrega G
Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?
2011-01-01 Geuna E; Milani A; Redana S; Rossi V; Valabrega G; Aglietta M; Montemurro F.
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib
2011-01-01 Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. | 2003 | VALABREGA G; FAGIOLI F; CORSO S; MADON E; BRACH DEL PREVER A; BIASIN E; LINARI A; M. AGLIETTA; GIORDANO S. | |
| Trastuzumab-based combination therapy for breast cancer | 2004 | MONTEMURRO F; VALABREGA G; AGLIETTA M | |
| The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005 | 2005 | MONTEMURRO F; VALABREGA G; GARETTO L; ALIBERTI S; GRIGNANI G; ORTEGA C; LEONE F; PONZONE R; AGLIETTA M | |
| TGFalpha expression impairs Trastuzumab-induced HER2 downregulation | 2005 | VALABREGA G; MONTEMURRO F; SAROTTO I; PETRELLI A; RUBINI P; TACCHETTI C; AGLIETTA M; COMOGLIO PM; GIORDANO S | |
| Controversies in breast cancer: adjuvant and neoadjuvant therapy | 2005 | F. MONTEMURRO; S. REDANA; G. VALABREGA; M. AGLIETTA | |
| Trastuzumab treatment in breast cancer | 2006 | MONTEMURRO F; VALABREGA G; AGLIETTA M | |
| Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer | 2006 | MONTEMURRO F; GATTI M; REDANA S; JACOMUZZI ME; NANNI D; DURANDO A; POPOLO M; PONZONE R; ROSSI A; ALBIERI V; VALABREGA G; SISMONDI P; GABRIELE P; AGLIETTA M | |
| Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy | 2006 | F. MONTEMURRO; M. DONADIO; M. CLAVAREZZA; S. REDANA; M.E. JACOMUZZI; G. VALABREGA; S. DANESE; G. VIETTI-RAMUS; A. DURANDO; M. VENTURINI; M. AGLIETTA | |
| Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007 | 2007 | MONTEMURRO F; REDANA S; VALABREGA G; AGLIETTA M | |
| Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer | 2007 | VALABREGA G; MONTEMURRO F; AGLIETTA M | |
| Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity | 2007 | MONTEMURRO F; VALABREGA G; AGLIETTA M | |
| Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era | 2008 | Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; Paolo dei Tos A; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M | |
| Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study | 2008 | MONTEMURRO F; REDANA S; NOLE' F; DONADIO M; JACOMUZZI ME; VALABREGA G; VIALE G; SAPINO A; AGLIETTA M | |
| Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial | 2008 | MONTEMURRO F; REDANA S; VALABREGA G; MARTINELLO R; AGLIETTA M; PALMIERO R | |
| Multitarget drugs: the present and the future of cancer therapy | 2009 | Petrelli A; Valabrega G. | |
| Trastuzumab Beyond Disease Progression: Case Closed? | 2009 | Valabrega G; Aglietta M; Montemurro F | |
| Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. | 2010 | Montemurro F; Rossi V; Nolè F; Redana S; Donadio M; Martinello R; Verri E; Valabrega G; Rocca MC; Jacomuzzi ME; Viale G; Sapino A; Aglietta M. | |
| Role of trastuzumab in the management of HER2-positive metastatic breast cancer. | 2010 | Milani A;Montemurro F;Gioeni L;Aglietta M;Valabrega G | |
| Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? | 2011 | Geuna E; Milani A; Redana S; Rossi V; Valabrega G; Aglietta M; Montemurro F. | |
| HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib | 2011 | Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile